Project Grant R44DA050368

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is aimed at implementing a low-threshold Hepatitis C (HCV) treatment strategy in a jail setting. The $252,042 award, effective September 15, 2024, will support a pilot study at Rhode Island Hospital to evaluate the feasibility and effectiveness of the "MINMON-J" approach, which modifies a minimal monitoring HCV treatment protocol for use...

This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $235,542 to Brigham & Women's Hospital Inc. to conduct a double-blind, randomized clinical trial evaluating the safety of using extended-release buprenorphine (XR-BUP) as a low-dose induction strategy for patients with opioid use disorder. The study aims to determine if XR-BUP can be safely administered before the emergence of opioid withdrawal...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The $398,137 award to Boston Interactome LLC will support research to identify small-molecule compounds that can disrupt key epigenetic protein complexes involved in mediating OUD, with the goal of developing an effective, epigenetically-targeted treatment for this...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to discover novel small molecule therapeutics for the safe and effective treatment of Opioid Use Disorder (OUD). The $798,828 award will support the development of an AI-powered drug discovery platform called M3.AI, which will integrate target-based and phenotype-based approaches to identify multi-cell type, multi-target polypharmacological...

This federal Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $19,302,777 to Nirsum Laboratories, Inc. to accelerate the development of NRS-033 towards Phase 3 trials and FDA registration for the treatment of opioid use disorder (OUD). The key products and services to be delivered include late-stage chemistry, manufacturing, and controls (CMC) for the active pharmaceutical ingredient (API) and...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $326,410 to Berkshire Biomedical Corporation to conduct a two-phased clinical study on the use of a hand-held, automated, personalized oral liquid dispensing system called COPATM for take-home methadone medication management for patients with opioid use disorder (OUD). The Phase I feasibility study will evaluate the functionality and acceptance...

This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,476,750 to Brigham & Women's Hospital Inc. to conduct a pilot randomized controlled trial evaluating semaglutide as an adjunct treatment to buprenorphine for individuals with opioid use disorder (OUD). The study aims to assess semaglutide's impact on attenuating cue-induced craving and its safety and tolerability over a 12-week period....

This $195,728 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a study to assess the acceptability and feasibility of using pharmacogenomic (PGx) testing to guide opioid use disorder (OUD) treatment. The key objectives are to: Identify barriers and facilitators to implementing a PGx testing protocol for OUD treatment by engaging patients, providers, and administrators. Develop and evaluate...